RTX-101
/ Repeat Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 15, 2026
A study to assess safety, tolerability, and pharmacokinetics of RTX-010/101/111 in healthy adults. Part 1A and Part B healthy participants only
(ANZCTR)
- P1 | N=104 | Recruiting | Sponsor: Repeat Therapeutics Pty Ltd | Initiation date: Nov 2025
First-in-human • Trial initiation date • Amyotrophic Lateral Sclerosis • CNS Disorders
1 to 1
Of
1
Go to page
1